GlassScriptPhysician profile
Christopher W Tsang
NPI 1104187525
$3,740.78
in general payments reported to CMS, 2019-2025
22 companies · $196 in 2025
The $196 reported for 2025 was less than what a typical Otolaryngology/Facial Plastic Surgery provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $763 · 2020: $617 · 2021: $732 · 2022: $783 · 2023: $613 · 2024: $36.61 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $846.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $846.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $935.74 | 2019-2023 | Dupixent |
| Optinose US, INC. | $866.49 | 2019-2023 | |
| Stryker Corporation | $395.79 | 2019-2023 | Latera, Xpress Ent Dilation System, Hemopore |
| Genzyme Corporation | $318.83 | 2021-2023 | |
| Medtronic, INC. | $196.30 | 2025 | Pteye Parathyroid Detection System |
| Intersect Ent, INC. | $165.80 | 2020-2022 | |
| Acclarent, INC | $159.44 | 2019-2021 | |
| Alk-Abello, INC | $119.79 | 2021-2023 | Odactra, Ragwitek, Grastek |
| Cochlear Americas | $112.00 | 2019 | |
| Integra Lifesciences Corporation | $110.59 | 2019-2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Neurent Medical Limited | $58.22 | 2022 | |
| Glaxosmithkline, LLC. | $57.99 | 2021-2023 | Nucala |
| Checkpoint Surgical, INC | $52.24 | 2019-2020 | |
| Inspire Medical Systems, INC. | $36.61 | 2024 | Inspire |
| Arbor Pharmaceuticals, INC. | $35.37 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $26.76 | 2021 | |
| Merz North America, INC. | $24.57 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.89 | 2020 | |
| Merck Sharp & Dohme LLC | $15.04 | 2022 | |
| Smith+Nephew, INC. | $14.08 | 2021 | |
| Med-El Corporation | $12.13 | 2022 | |
| Aerin Medical INC. | $11.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Tsang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.